Hodges GW, et al. - Whether treatment with Simvastatin 40 mg and Ezetimibe 10 mg lowered plasma soluble urokinase plasminogen activator receptor (suPAR) levels in patients with mild-moderate, asymptomatic aortic stenosis, was investigated herein. The progression of the time-related increase in plasma suPAR levels was noted to be hindered as a result of simvastatin and Ezetimibe treatment. Also, year-1 suPAR was shown to be related to all-cause mortality, major cardiovascular events, and aortic valve-related events irrespective of baseline levels.